Business Description
Soleno Therapeutics Inc
NAICS : 541713
SIC : 2834
ISIN : US8342032005
Description
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.
Financial Strength
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 431.2 | |||||
Equity-to-Asset | 0.85 | |||||
Debt-to-EBITDA | -0.01 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 2/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 32.3 | |||||
3-Year EPS without NRI Growth Rate | 34 | |||||
3-Year FCF Growth Rate | 37 | |||||
3-Year Book Growth Rate | -16.6 |
Momentum Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 27.34 | |||||
9-Day RSI | 38.88 | |||||
14-Day RSI | 43.87 | |||||
6-1 Month Momentum % | 21 | |||||
12-1 Month Momentum % | 867.71 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 11.23 | |||||
Quick Ratio | 11.23 | |||||
Cash Ratio | 11.11 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -81.4 | |||||
Shareholder Yield % | -8.81 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -76.7 | |||||
ROA % | -56.12 | |||||
ROIC % | -292.49 | |||||
ROC (Joel Greenblatt) % | -14039.31 | |||||
ROCE % | -68.15 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 9.74 | |||||
Price-to-Tangible-Book | 10.35 | |||||
EV-to-EBIT | -26.45 | |||||
EV-to-EBITDA | -27.45 | |||||
EV-to-Forward-Revenue | 7.82 | |||||
EV-to-FCF | -46.08 | |||||
Price-to-Net-Current-Asset-Value | 11.11 | |||||
Price-to-Net-Cash | 11.26 | |||||
Earnings Yield (Greenblatt) % | -3.78 | |||||
FCF Yield % | -1.99 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:SLNO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Soleno Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -2.707 | ||
Beta | -3.21 | ||
Volatility % | 503 | ||
14-Day RSI | 43.87 | ||
14-Day ATR ($) | 2.433921 | ||
20-Day SMA ($) | 43.3835 | ||
12-1 Month Momentum % | 867.71 | ||
52-Week Range ($) | 3.69 - 53.82 | ||
Shares Outstanding (Mil) | 36.86 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 2 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Soleno Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Soleno Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Soleno Therapeutics Inc Frequently Asked Questions
What is Soleno Therapeutics Inc(SLNO)'s stock price today?
The current price of SLNO is $41.90. The 52 week high of SLNO is $53.82 and 52 week low is $3.69.
When is next earnings date of Soleno Therapeutics Inc(SLNO)?
The next earnings date of Soleno Therapeutics Inc(SLNO) is 2024-08-08 Est..
Does Soleno Therapeutics Inc(SLNO) pay dividends? If so, how much?
Soleno Therapeutics Inc(SLNO) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |